AC
YMAB

Athanor Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Athanor Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,600
Closed -$215K – 836
2020
Q3 		$215K Sell
5,600
-2,860
-34% -$114K 0.01% 481
2020
Q2 		$365K Buy
+8,460
New +$320K 0.02% 368

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Athanor Capital's YMAB Position: Q4 2020 in Review

Athanor Capital sold out of Y-mAbs Therapeutics (YMAB) in Q4 2020, closing a stake of 5,600 shares — an estimated $215K sold.

Athanor Capital first reported a position in YMAB in Q2 2020 and held it in 2 quarters. The position peaked at $365K in Q2 2020. 114 funds tracked by Wall St. Rank hold YMAB as of Q4 2020.

  • Athanor Capital reported no remaining Y-mAbs Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Athanor Capital sold 5,600 Y-mAbs Therapeutics shares in Q4 2020, an estimated $215K.
  • Athanor Capital first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 2 quarters.
  • Athanor Capital's Y-mAbs Therapeutics position peaked at $365K in Q2 2020.
  • 114 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.